Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 12097 results found since Jan 2013.
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus
CONCLUSION: The results of this meta-analysis indicate that alendronate combined with atorvastatin is a better treatment for osteoporosis in diabetes mellitus, showing more effective and higher BMD and fewer adverse events than alendronate alone.PMID:35178452 | PMC:PMC8844385 | DOI:10.1155/2022/6747469
Source: Biomed Res - February 18, 2022 Category: Research Authors: Zhencheng Xiong Ping Yi Xiangsheng Tang Li Shu Chi Zhang Source Type: research
Cost-benefit analysis of new lipid-lowering agents
Herz. 2022 Apr 25. doi: 10.1007/s00059-022-05116-8. Online ahead of print.ABSTRACTPatients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when consideri...
Source: Herz - April 25, 2022 Category: Cardiology Authors: Christopher Blaum Natalie Arnold Christoph Waldeyer Source Type: research
New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
AbstractPurpose of ReviewThe primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein cholesterol (LDL-C) lowering. Typically, statin therapy remains the first-line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the US Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD ...
Source: Current Cardiovascular Risk Reports - June 25, 2022 Category: Cardiology Source Type: research
Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
In conclusion, concomitant use of statin seemed to have no significant influence on the survival of patients with NSCLC who were treated with ICIs.PMID:35855055 | PMC:PMC9276478 | DOI:10.1155/2022/3429462
Source: Clinical Lung Cancer - July 20, 2022 Category: Cancer & Oncology Authors: Lei Zhang Hong Wang Jizheng Tian Lili Sui Xiaoyan Chen Source Type: research
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
AbstractPurpose of ReviewSince the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination with statins and/or ezetimibe. These powerful treatments reduce the incidence of atheroscler...
Source: Current Atherosclerosis Reports - July 29, 2022 Category: Cardiology Source Type: research
Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals
Dose Response. 2022 Sep 21;20(3):15593258221120485. doi: 10.1177/15593258221120485. eCollection 2022 Jul-Sep.ABSTRACTPhytochemicals (Pch) present in fruits, vegetables and other foods, are known to inhibit or induce drug metabolism and transport. An exhaustive search was performed in five databases covering from 2000 to 2021. Twenty-one compounds from plants were found to modulate CYP3A and/or P-gp activities and modified the pharmacokinetics and the therapeutic effect of 27 different drugs. Flavonols, flavanones, flavones, stilbenes, diferuloylmethanes, tannins, protoalkaloids, flavans, hyperforin and terpenes, reduce pla...
Source: Dose Response - September 26, 2022 Category: Drugs & Pharmacology Authors: Josefina G ómez-Garduño Renato Le ón-Rodríguez Radam és Alemón-Medina Beatriz E P érez-Guillé Rosa E Soriano-Rosales Ailema Gonz ález-Ortiz Juan L Ch ávez-Pacheco Edelmira Solorio-L ópez Paola Fernandez-P érez Liliana Rivera-Espinosa Source Type: research
Approach to risk stratification of atherosclerotic cardiovascular disease: Use of biomarkers and imaging in a Canadian context
CONCLUSION: Biomarkers and imaging tests have the potential to improve ASCVD risk stratification by reclassifying any patient whose risk has been inaccurately estimated by traditional methods. Recently published guidelines by the CCS suggest the use of biomarkers and imaging in certain patient groups.PMID:36100373 | PMC:PMC9470181 | DOI:10.46747/cfp.6809654
Source: Canadian Family Physician Medecin de Famille Canadien - September 13, 2022 Category: Primary Care Authors: Daniel Esau Beth L Abramson Source Type: research
